Eden Research plc (EDEN) - Total Liabilities
Based on the latest financial reports, Eden Research plc (EDEN) has total liabilities worth GBX2.85 Million GBX (≈ $347.13 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Eden Research plc (EDEN) long-term investment share to see how much of total assets are deployed in long-term investments.
Eden Research plc - Total Liabilities Trend (2004–2024)
This chart illustrates how Eden Research plc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see EDEN asset base.
Eden Research plc Competitors by Total Liabilities
The table below lists competitors of Eden Research plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JDC Group AG
XETRA:JDC
|
Germany | €174.34 Million |
|
Mineral & Financial Investments Ltd
LSE:MAFL
|
UK | GBX518.00K |
|
ImmuPharma PLC
LSE:IMM
|
UK | GBX1.24 Million |
|
Rua Life Sciences PLC
LSE:RUA
|
UK | GBX1.89 Million |
|
Artisanal Spirits Company PLC
LSE:ART
|
UK | GBX40.89 Million |
|
Vicarious Surgical Inc.
NYSE:RBOT
|
USA | $9.02 Million |
Liability Composition Analysis (2004–2024)
This chart breaks down Eden Research plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Eden Research plc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eden Research plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eden Research plc (2004–2024)
The table below shows the annual total liabilities of Eden Research plc from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX3.57 Million ≈ $434.15 |
+17.03% |
| 2023-12-31 | GBX3.05 Million ≈ $370.97 |
+40.59% |
| 2022-12-31 | GBX2.17 Million ≈ $263.86 |
-1.32% |
| 2021-12-31 | GBX2.20 Million ≈ $267.39 |
+10.13% |
| 2020-12-31 | GBX2.00 Million ≈ $242.78 |
+31.53% |
| 2019-12-31 | GBX1.52 Million ≈ $184.59 |
+60.90% |
| 2018-12-31 | GBX942.87K ≈ $114.72 |
-54.49% |
| 2017-12-31 | GBX2.07 Million ≈ $252.10 |
+100.63% |
| 2016-12-31 | GBX1.03 Million ≈ $125.66 |
+37.23% |
| 2015-12-31 | GBX752.55K ≈ $91.56 |
+64.20% |
| 2014-12-31 | GBX458.30K ≈ $55.76 |
-46.34% |
| 2013-12-31 | GBX854.09K ≈ $103.92 |
-59.22% |
| 2012-12-31 | GBX2.09 Million ≈ $254.86 |
-27.97% |
| 2011-12-31 | GBX2.91 Million ≈ $353.82 |
-48.77% |
| 2010-12-31 | GBX5.68 Million ≈ $690.61 |
+37.80% |
| 2009-12-31 | GBX4.12 Million ≈ $501.16 |
+24.44% |
| 2008-12-31 | GBX3.31 Million ≈ $402.72 |
+19.83% |
| 2007-12-31 | GBX2.76 Million ≈ $336.09 |
-14.34% |
| 2006-12-31 | GBX3.22 Million ≈ $392.36 |
+45.99% |
| 2005-12-31 | GBX2.21 Million ≈ $268.76 |
+96.65% |
| 2004-12-31 | GBX1.12 Million ≈ $136.66 |
-- |
About Eden Research plc
Eden Research plc, together with its subsidiaries, engages in the development and sale of biopesticides in Europe and the United Kingdom. The company offers foliar disease and insect control, open field and greenhouses, soil pests, post-harvest shelf-life extension, and seed treatments under the Mevalone and Cedroz brands for crop protection applications. It also provides consume products, such a… Read more